Elevation Oncology Inc
NASDAQ:ELEV
Elevation Oncology Inc
NASDAQ:ELEV
Price:
3.55 USD
-7.79%
Updated:
May 1, 2024
Elevation Oncology Inc
Cash from Financing Activities
|
Elevation Oncology Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Elevation Oncology Inc
NASDAQ:ELEV
|
Cash from Financing Activities
$48m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Elevation Oncology Inc's Cash from Financing Activities?
Cash from Financing Activities
48m
USD
48m
USD
Based on the financial report for Dec 31, 2023, Elevation Oncology Inc's Cash from Financing Activities amounts to 48m USD.
What is Elevation Oncology Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-19%
-19%
Over the last year, the Cash from Financing Activities growth was 63%. The average annual Cash from Financing Activities growth rates for Elevation Oncology Inc have been -19% over the past three years .
You don't have any saved screeners yet
